Journal of Pharmacological Reports

OPEN ACCESS Freely available online

Editorial

Combined Evidence from Individual Cases over Half a Hundred Years Collected Globally

Sarah Watson*

Uppsala Monitoring Centre, Uppsala S-751 40, Sweden

EDITORIAL

Adverse drug reactions (ADRs) are a crucial explanation for morbidity and mortality. Reports on differences in reporting patterns between women and men exist nationally. The goal of this study was to assess the worldwide evidence on spontaneous post-marketing ADR reporting differences be- tween reports for ladies and men. Methods: We analyzed data collected within VigiBase, the WHO global database of individual case safety reports, between 1967-2 January 2018. VigiBase contains quite 18 million reports from the 131 member countries of the WHO Programme for International Drug Monitoring. Findings: Of the reports with information on sex, 9,056,566 (60.1%) concerned female and 6,012,804 (39.9%) male children and adults. More female ADR reports were submitted altogether regions of the planet and by all kinds of reporters. A higher proportion of female reports was seen altogether age bracket s from the age group 12-17 years and older. The largest difference was observed within the age group of 18–44 years and cannot be explained by hormonal contraceptive use. The proportion of great and fatal reports was higher for male reports.

Several studies have shown sex differences in national data on reported adverse drug reactions (ADRs), which consistently show more female than male reports of ADRs. Global reporting patterns however haven't been reported before. This study shows that more ADR reports are submitted for ladies from all regions of the planet and by all kinds of reporters. There are more female ADR reports altogether age groups from puberty and onwards. The largest difference was observed within the age bracket 18–44 years and will not be explained by hormonal con- traceptive use. The proportion of great and fatal reports is higher among male reports than female reports using global spontaneous ADR reporting data. This study underscores the importance of sex and gender in medicine. The differences in reporting patterns between women and men implicate that further studies are needed to spot the underlying reasons for female dominance, especially around reproductive age. Women got to be enrolled into clinical trials to an identical degree as men and data in clinical trials must be stratified and analysed by sex to raised understand sex and gender differences in ADRs.

Women are thought to be more in danger for ADRs not only be- cause they use more drugs but also thanks to differences in pharmacokinetic and pharmacodynamic effects of drugs and therefore the incontrovertible fact that they use higher doses in reference to their weight. A thorough review of 300 new drug applications between 1995 and 2000 to the us Food and Drug Administration (FDA) showed that out of 163 applications that included an analysis by sex, 11 demonstrated a difference of 40% or more in pharmacokinetics between women and men. Apart from pharmacokinetic and pharmacodynamic differences between women and men, drug-induced cardiac arrhythmias, including torsade de pointes, indicate that factors other than differences in body composition and pharmacokinetics could also be involved within the occurrence of ADRs that differ between the sexes. Healthcare professionals can also report ADRs for ladies more often than for men, even when adjusted for dispensed drugs and age-related differences. This was seen in a Swedish study investigating the reporting patterns of healthcare professionals. Regarding seriousness of the reports, men were reported to experience more serious ADRs as compared to women.

***Correspondence to:** Sarah Watson, Uppsala Monitoring Centre, Uppsala S-751 40, Sweden. E-mail: sarah.watson@who-umc.org

Received: July 12, 2021; **Accepted:** July 19, 2021; **Published:** July 26, 2021

Citation: Watson S (2021) Combined evidence from individual cases over half a hundred years collected globally. J Pharma Reports 5: 114.